Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models

Advanced Drug Delivery Reviews

Volumn 85, Issue , 2015, Pages 44-56

  Hittinger, Marius ^a   Juntke, Jenny ^a   Kletting, Stephanie ^a   Schneider Daum, Nicole ^a   de Souza Carvalho, Cristiane ^a   Lehr, Claus Michael ^a,b  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

3R principle; A549; Alternatives to animal testing; Anti infectives; Calu 3; Cell culture models; Cystic fibrosis; Disease relevant models; Pneumonia; Tuberculosis

Indexed keywords

ANIMAL CELL CULTURE; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; TARGETED DRUG DELIVERY;

3R PRINCIPLE; A549; ANIMAL TESTING; ANTI-INFECTIVES; CALU-3; CELL CULTURE MODELS; CYSTIC FIBROSIS; PNEUMONIA; TUBERCULOSIS;

PHYSIOLOGICAL MODELS;

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BCG VACCINE; CEFACLOR; CLARITHROMYCIN; ERYTHROMYCIN; NANOPARTICLE; RIFAMPICIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ASTHMA; BRONCHUS MUCOSA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DISEASE MODEL; DRUG CHOICE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; EX VIVO STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS EPITHELIUM CELL; LUNG INFECTION; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; ADVERSE EFFECTS; ANIMAL; ANIMAL TESTING ALTERNATIVE; DRUG DELIVERY SYSTEM; MICROBIOLOGY; PNEUMONIA, BACTERIAL; PRECLINICAL STUDY; PROCEDURES; TUBERCULOSIS, PULMONARY;

ANIMAL USE ALTERNATIVES; ANIMALS; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; IN VITRO TECHNIQUES; PNEUMONIA, BACTERIAL; TUBERCULOSIS, PULMONARY;

EID: 84930082170     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.10.011     Document Type: Review

References (180)

1. Nahar K., Gupta N., Gauvin R., Absar S., Patel B., Gupta V., Khademhosseini A., Ahsan F. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. Eur. J. Pharm. Sci. 2013, 49:805-818.
2. Pandey R., Khuller G.K. Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemother. 2005, 55:430-435.
3. Pandey R., Ahmad Z. Nanomedicine and experimental tuberculosis: facts, flaws, and future. Nanomedicine 2011, 7:259-272.
4. Scheuch G., Kohlhaeufl M.J., Brand P., Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv. Drug Deliv. Rev. 2006, 58:996-1008.
5. Fernandes C.A., Vanbever R. Preclinical models for pulmonary drug delivery. Expert Opin. Drug Deliv. 2009, 6:1231-1245.
6. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 2006, 58:1030-1060.
7. Patton J.S., Brain J.D., Davies L.A., Fiegel J., Gumbleton M., Kim K.J., Sakagami M., Vanbever R., Ehrhardt C. The particle has landed-characterizing the fate of inhaled pharmaceuticals. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23.
8. Ruge C.A., Kirch J., Lehr C.M. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. Lancet Respir. Med. 2013, 1:402-413.
9. Shoyele S.A., Slowey A. Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int. J. Pharm. 2006, 314:1-8.
10. Steimer A., Haltner E., Lehr C.M. Cell culture models of the respiratory tract relevant to pulmonary drug delivery. J. Aerosol Med. 2005, 18:137-182.
11. Endter S., Becker U., Daum N., Huwer H., Lehr C.-M., Gumbleton M., Ehrhardt C. P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers. Cell Tissue Res. 2006, 328:77-84.
12. de Souza Carvalho C., Daum N., Lehr C.M. Carrier interactions with the biological barriers of the lung: advanced in vitro models and challenges for pulmonary drug delivery. Adv. Drug Deliv. Rev. 2014, 29:124-126.
13. Andes D., Craig W.A. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 2002, 19:261-268.
14. White R.L. What in vitro models of infection can and cannot do. Pharmacotherapy 2001, 21:292S-301S.
15. McGonigle P., Ruggeri B. Animal models of human disease: challenges in enabling translation. Biochem. Pharmacol. 2014, 87:162-171.
16. van Heeckeren A.M., Schluchter M.D. Murine models of chronic Pseudomonas aeruginosa lung infection. Lab. Anim. 2002, 36:291-312.
17. Barrios R. Animal models of lung disease. Molecular Pathology of Lung Diseases 2008, 144-149. Springer, New York. D. Zander, H. Popper, J. Jagirdar, A. Haque, P. Cagle, R. Barrios (Eds.).
18. Neuhaus V., Schwarz K., Klee A., Seehase S., Forster C., Pfennig O., Jonigk D., Fieguth H.G., Koch W., Warnecke G., Yusibov V., Sewald K., Braun A. Functional testing of an inhalable nanoparticle based influenza vaccine using a human precision cut lung slice technique. PLoS ONE 2013, 8.
19. Ally J., Amirfazli A., Roa W. Factors affecting magnetic retention of particles in the upper airways: an in vitro and ex vivo study. J. Aerosol Med. 2006, 19:491-509.
20. Li M., Byron P.R. Tobramycin disposition in the rat lung following airway administration. J. Pharmacol. Exp. Ther. 2013, 347:318-324.
21. Henning A., Schneider M., Bur M., Blank F., Gehr P., Lehr C.M. Embryonic chicken trachea as a new in vitro model for the investigation of mucociliary particle clearance in the airways. AAPS PharmSciTech 2008, 9:521-527.
22. Henning A., Schneider M., Nafee N., Muijs L., Rytting E., Wang X., Kissel T., Grafahrend D., Klee D., Lehr C.M. Influence of particle size and material properties on mucociliary clearance from the airways. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23:233-241.
23. Kirch J., Guenther M., Doshi N., Schaefer U.F., Schneider M., Mitragotri S., Lehr C.M. Mucociliary clearance of micro- and nanoparticles is independent of size, shape and charge-an ex vivo and in silico approach. J. Control. Release 2012, 159:128-134.
24. Harrison F., Muruli A., Higgins S., Diggle S.P. Development of an ex vivo porcine lung model for studying growth, virulence, and signaling of Pseudomonas aeruginosa. Infect. Immun. 2014, 82:3312-3323.
25. Sauer U.G., Vogel S., Aumann A., Hess A., Kolle S.N., Ma-Hock L., Wohlleben W., Dammann M., Strauss V., Treumann S., Groters S., Wiench K., van Ravenzwaay B., Landsiedel R. Applicability of rat precision-cut lung slices in evaluating nanomaterial cytotoxicity, apoptosis, oxidative stress, and inflammation. Toxicol. Appl. Pharmacol. 2014, 276:1-20.
26. Sewald K., Braun A. Assessment of immunotoxicity using precision-cut tissue slices. Xenobiotica 2013, 43:84-97.
27. Sewald K., Lauenstein L., Schneider X., Pirow R., Steinfath M., Ma-Hock L., Liebsch M., Landsiedel R., a.M.A., Braun C. 9th World Congress on Alternatives and Animal Use in the Life Sciences 2014, 146. (Prague). D. Jírová, H. Spielmann (Eds.).
28. Klein S.G., Hennen J., Serchi T., Blömeke B., Gutleb A.C. Potential of coculture in vitro models to study inflammatory and sensitizing effects of particles on the lung. Toxicol. in Vitro 2011, 25:1516-1534.
29. Ochs M., Weibel E.R. Functional Design of the Human Lung for Gas Exchange 2008, McGray-Hill Medical.
30. Wilson A. Cytotoxicity and Viability Assays in Animal Cell Culture: A Practical Approach 1986, IRL press, Oxford.
31. Elbert K.J., Schafer U.F., Schafers H.J., Kim K.J., Lee V.H., Lehr C.M. Monolayers of human alveolar epithelial cells in primary culture for pulmonary absorption and transport studies. Pharm. Res. 1999, 16:601-608.
32. Forbes B. Human airway epithelial cell lines for in vitro drug transport and metabolism studies. Pharm. Sci. Technol. Today 2000, 3:18-27.
33. Grainger C.I., Greenwell L.L., Lockley D.J., Martin G.P., Forbes B. Culture of calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm. Res. 2006, 23:1482-1490.
34. Letoha T., Kusz E., Papai G., Szabolcs A., Kaszaki J., Varga I., Takacs T., Penke B., Duda E. In vitro and in vivo nuclear factor-kappaB inhibitory effects of the cell-penetrating penetratin peptide. Mol. Pharmacol. 2006, 69:2027-2036.
35. Cuervo A.M. Autophagy: in sickness and in health. Trends Cell Biol. 2004, 14:70-77.
36. Levine B., Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell 2004, 6:463-477.
37. Stern S.T., Adiseshaiah P.P., Crist R.M. Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. Part. Fibre Toxicol. 2012, 9:1743-8977.
38. Ehrhardt C., Kneuer C., Fiegel J., Hanes J., Schaefer U., Kim K.-J., Lehr C.-M. Influence of apical fluid volume on the development of functional intercellular junctions in the human epithelial cell line 16HBE14o-: implications for the use of this cell line as an in vitro model for bronchial drug absorption studies. Cell Tissue Res. 2002, 308:391-400.
39. Forbes B., Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. Eur. J. Pharm. Biopharm. 2005, 60:193-205.
40. Manford F., Tronde A., Jeppsson A.B., Patel N., Johansson F., Forbes B. Drug permeability in 16HBE14o- airway cell layers correlates with absorption from the isolated perfused rat lung. Eur. J. Pharm. Sci. 2005, 26:414-420.
41. Vllasaliu D., Shubber S., Fowler R., Garnett M., Alexander C., Stolnik S. Epithelial toxicity of alkylglycoside surfactants. J. Pharm. Sci. 2013, 102:114-125.
42. Arnold J.J., Ahsan F., Meezan E., Pillion D.J. Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells. J. Pharm. Sci. 2004, 93:2205-2213.
43. Ahsan F., Arnold J.J., Yang T., Meezan E., Schwiebert E.M., Pillion D.J. Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-beta-cyclodextrin, on insulin movement across human bronchial epithelial cells (16HBE14o-). Eur. J. Pharm. Sci. 2003, 20:27-34.
44. Soane R.J., Frier M., Perkins A.C., Jones N.S., Davis S.S., Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int. J. Pharm. 1999, 178:55-65.
45. Smith J.M., Dornish M., Wood E.J. Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. Biomaterials 2005, 26:3269-3276.
46. Florea B.I., Thanou M., Junginger H.E., Borchard G. Enhancement of bronchial octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation. J. Control. Release 2006, 110:353-361.
47. Vllasaliu D., Exposito-Harris R., Heras A., Casettari L., Garnett M., Illum L., Stolnik S. Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int. J. Pharm. 2010, 400:183-193.
48. Lin H., Li H., Cho H.J., Bian S., Roh H.J., Lee M.K., Kim J.S., Chung S.J., Shim C.K., Kim D.D. Air-liquid interface (ALI) culture of human bronchial epithelial cell monolayers as an in vitro model for airway drug transport studies. J. Pharm. Sci. 2007, 96:341-350.
49. Becker S., Dailey L., Soukup J.M., Silbajoris R., Devlin R.B. TLR-2 is involved in airway epithelial cell response to air pollution particles. Toxicol. Appl. Pharmacol. 2005, 203:45-52.
50. Perkins T.N., Shukla A., Peeters P.M., Steinbacher J.L., Landry C.C., Lathrop S.A., Steele C., Reynaert N.L., Wouters E.F., Mossman B.T. Differences in gene expression and cytokine production by crystalline vs. amorphous silica in human lung epithelial cells. Part. Fibre Toxicol. 2012, 9:1743-8977.
51. Reddel R.R., De Silva R., Duncan E.L., Rogan E.M., Whitaker N.J., Zahra D.G., Ke Y., McMenamin M.G., Gerwin B.I., Harris C.C. SV40-induced immortalization and ras-transformation of human bronchial epithelial cells. Int. J. Cancer 1995, 61:199-205.
52. Ge Q., Moir L.M., Black J.L., Oliver B.G., Burgess J.K. TGFbeta1 induces IL-6 and inhibits IL-8 release in human bronchial epithelial cells: the role of Smad2/3. J. Cell. Physiol. 2010, 225:846-854.
53. Lehmann A.D., Daum N., Bur M., Lehr C.-M., Gehr P., Rothen-Rutishauser B.M. An in vitro triple cell co-culture model with primary cells mimicking the human alveolar epithelial barrier. Eur. J. Pharm. Biopharm. 2011, 77:398-406.
54. Sporty J.L., Horalkova L., Ehrhardt C. In vitro cell culture models for the assessment of pulmonary drug disposition. Expert Opin. Drug Metab. Toxicol. 2008, 4:333-345.
55. + channel function. An in vitro model. J. Biol. Chem. 2005, 280:24181-24187.
56. Woollhead A.M., Baines D.L. Forskolin-induced cell shrinkage and apical translocation of functional enhanced green fluorescent protein-human alphaENaC in H441 lung epithelial cell monolayers. J. Biol. Chem. 2006, 281:5158-5168.
57. Winkelmann A., Noack T. The Clara cell: a "Third Reich eponym"?. Eur. Respir. J. 2010, 36:722-727.
58. Salomon J.J., Muchitsch V.E., Gausterer J.C., Schwagerus E., Huwer H., Daum N., Lehr C.M., Ehrhardt C. The cell line NCl-H441 is a useful in vitro model for transport studies of human distal lung epithelial barrier. Mol. Pharmacol. 2014, 20:20.
59. Stone K.C., Mercer R.R., Gehr P., Stockstill B., Crapo J.D. Allometric relationships of cell numbers and size in the mammalian lung. Am. J. Respir. Cell Mol. Biol. 1992, 6:235-243.
60. Daum N., Kuehn A., Hein S., Schaefer U.F., Huwer H., Lehr C.M. Isolation, cultivation, and application of human alveolar epithelial cells. Methods Mol. Biol. 2012, 806:31-42.
61. Fuchs S., Hollins A.J., Laue M., Schaefer U.F., Roemer K., Gumbleton M., Lehr C.M. Differentiation of human alveolar epithelial cells in primary culture: morphological characterization and synthesis of caveolin-1 and surfactant protein-C. Cell Tissue Res. 2003, 311:31-45.
62. Kemp S.J., Thorley A.J., Gorelik J., Seckl M.J., O'Hare M.J., Arcaro A., Korchev Y., Goldstraw P., Tetley T.D. Immortalization of human alveolar epithelial cells to investigate nanoparticle uptake. Am. J. Respir. Cell Mol. Biol. 2008, 39:591-597.
63. van den Bogaard E.H.J., Dailey L.A., Thorley A.J., Tetley T.D., Forbes B. Inflammatory response and barrier properties of a new alveolar type 1-like cell line (TT1). Pharm. Res. 2009, 26:1172-1180.
64. Pan H., Zhang Y., Luo Z., Li P., Liu L., Wang C., Wang H., Li H., Ma Y. Autophagy mediates avian influenza H5N1 pseudotyped particle-induced lung inflammation through NF-kappaB and p38 MAPK signaling pathways. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014, 306:15.
65. Gupta R., Yang J., Dong Y., Swiatlo E., Zhang J.R., Metzger D.W., Bai G. Deletion of arcD in Streptococcus pneumoniae D39 impairs its capsule and attenuates virulence. Infect. Immun. 2013, 81:3903-3911.
66. Fine K.L., Metcalfe M.G., White E., Virji M., Karls R.K., Quinn F.D. Involvement of the autophagy pathway in trafficking of Mycobacterium tuberculosis bacilli through cultured human type II epithelial cells. Cell. Microbiol. 2012, 14:1402-1414.
67. Kobayashi S., Kondo S., Juni K. Permeability of peptides and proteins in human cultured alveolar A549 cell monolayer. Pharm. Res. 1995, 12:1115-1119.
68. Kim K.J., Borok Z., Crandall E.D. A useful in vitro model for transport studies of alveolar epithelial barrier. Pharm. Res. 2001, 18:253-255.
69. Wang Z., Zhang Q. Transport of proteins and peptides across human cultured alveolar A549 cell monolayer. Int. J. Pharm. 2004, 269:451-456.
70. Moschini E., Gualtieri M., Colombo M., Fascio U., Camatini M., Mantecca P. The modality of cell-particle interactions drives the toxicity of nanosized CuO and TiO(2) in human alveolar epithelial cells. Toxicol. Lett. 2013, 222:102-116.
71. Saigal A., Ng W.K., Tan R.B., Chan S.Y. Development of controlled release inhalable polymeric microspheres for treatment of pulmonary hypertension. Int. J. Pharm. 2013, 450:114-122.
72. Kendall M., Ding P., Mackay R.M., Deb R., McKenzie Z., Kendall K., Madsen J., Clark H. Surfactant protein D (SP-D) alters cellular uptake of particles and nanoparticles. Nanotoxicology 2013, 7:963-973.
73. Rothen-Rutishauser B.M., Kiama S.G., Gehr P. A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. Am. J. Respir. Cell Mol. Biol. 2005, 32:281-289.
74. Grabowski N., Hillaireau H., Vergnaud J., Santiago L.A., Kerdine-Romer S., Pallardy M., Tsapis N., Fattal E. Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells. Int. J. Pharm. 2013, 454:686-694.
75. Sauer U.G., Vogel S., Hess A., Kolle S.N., Ma-Hock L., van Ravenzwaay B., Landsiedel R. In vivo-in vitro comparison of acute respiratory tract toxicity using human 3D airway epithelial models and human A549 and murine 3T3 monolayer cell systems. Toxicol. in Vitro 2013, 27:174-190.
76. Salomon J.J., Galeron P., Schulte N., Morow P.R., Severynse-Stevens D., Huwer H., Daum N., Lehr C.M., Hickey A.J., Ehrhardt C. Biopharmaceutical in vitro characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis. Ther. Deliv. 2013, 4:915-923.
77. Cavet M.E., West M., Simmons N.L. Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells. Antimicrob. Agents Chemother. 1997, 41:2693-2698.
78. Ong H.X., Traini D., Bebawy M., Young P.M. Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model. Antimicrob. Agents Chemother. 2013, 57:2535-2540.
79. Ong H.X., Traini D., Salama R., Anderson S.D., Daviskas E., Young P.M. The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia. Mol. Pharm. 2013, 10:2915-2924.
80. Rojanarat W., Nakpheng T., Thawithong E., Yanyium N., Srichana T. Inhaled pyrazinamide proliposome for targeting alveolar macrophages. Drug Deliv. 2012, 19:334-345.
81. Foster K.A., Oster C.G., Mayer M.M., Avery M.L., Audus K.L. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp. Cell Res. 1998, 243:359-366.
82. Chowdhury F., Howat W.J., Phillips G.J., Lackie P.M. Interactions between endothelial cells and epithelial cells in a combined cell model of airway mucosa: effects on tight junction permeability. Exp. Lung Res. 2010, 36:1-11.
83. Hermanns M.I., Unger R.E., Kehe K., Peters K., Kirkpatrick C.J. Lung epithelial cell lines in coculture with human pulmonary microvascular endothelial cells: development of an alveolo-capillary barrier in vitro. Lab. Investig. 2004, 84:736-752.
84. Papritz M., Pohl C., Wübbeke C., Moisch M., Hofmann H., Hermanns M.I., Thiermann H., Kirkpatrick C.J., Kehe K. Side-specific effects by cadmium exposure: apical and basolateral treatment in a coculture model of the blood-air barrier. Toxicol. Appl. Pharmacol. 2010, 245:361-369.
85. Kasper J., Hermanns M.I., Bantz C., Maskos M., Stauber R., Pohl C., Unger R.E., Kirkpatrick J.C. Inflammatory and cytotoxic responses of an alveolar-capillary coculture model to silica nanoparticles: comparison with conventional monocultures. Part. Fibre Toxicol. 2011, 8:6.
86. Hermanns M.I., Kasper J., Dubruel P., Pohl C., Uboldi C., Vermeersch V., Fuchs S., Unger R.E., Kirkpatrick C.J. An impaired alveolar-capillary barrier in vitro: effect of proinflammatory cytokines and consequences on nanocarrier interaction. J. R. Soc. Interface 2009, 7:S41-S54.
87. Korpi-Steiner N.L., Valkenaar S.M., Bates M.E., Evans M.D., Gern J.E., Bertics P.J. Human monocytic cells direct the robust release of CXCL10 by bronchial epithelial cells during rhinovirus infection. Clin. Exp. Allergy 2010, 40:1203-1213.
88. Torvinen M., Campwala H., Kilty I. The role of IFN-γ in regulation of IFN-γ-inducible protein 10 (IP-10) expression in lung epithelial cell and peripheral blood mononuclear cell co-cultures. Respir. Res. 2007, 8:80.
89. Blank F., Wehrli M., Lehmann A., Baum O., Gehr P., von Garnier C., Rothen-Rutishauser B.M. Macrophages and dendritic cells express tight junction proteins and exchange particles in an in vitro model of the human airway wall. Immunobiology 2011, 216:86-95.
90. Rothen-Rutishauser B., Mühlfeld C., Blank F., Musso C., Gehr P. Translocation of particles and inflammatory responses after exposure to fine particles and nanoparticles in an epithelial airway model. Part. Fibre Toxicol. 2007, 4:9.
91. Müller L., Riediker M., Wick P., Mohr M., Gehr P., Rothen-Rutishauser B. Oxidative stress and inflammation response after nanoparticle exposure: differences between human lung cell monocultures and an advanced three-dimensional model of the human epithelial airways. J. R. Soc. Interface 2010, 6:8.
92. Noguchi C., Umino T., Miyazaki Y., Jinta T., Usui Y., Yoshizawa Y. TGF-beta and glutathione promote tissue repair in cigarette smoke induced injury. J. Med. Dent. Sci. 2007, 54:109-116.
93. Araya J., Cambier S., Markovics J.A., Wolters P., Jablons D., Hill A., Finkbeiner W., Jones K., Broaddus V.C., Sheppard D., Barzcak A., Xiao Y., Erle D.J., Nishimura S.L. Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J. Clin. Investig. 2007, 117:3551-3562.
94. Liu Y., Gao W., Zhang D. Effects of cigarette smoke extract on A549 cells and human lung fibroblasts treated with transforming growth factor-β1 in a coculture system. Clin. Exp. Med. 2009, 10:159-167.
95. Pohl C., Hermanns M.I., Uboldi C., Bock M., Fuchs S., Dei-Anang J., Mayer E., Kehe K., Kummer W., Kirkpatrick C.J. Barrier functions and paracellular integrity in human cell culture models of the proximal respiratory unit. Eur. J. Pharm. Biopharm. 2009, 72:339-349.
96. Alfaro-Moreno E., Nawrot T.S., Vanaudenaerde B.M., Hoylaerts M.F., Vanoirbeek J.A., Nemery B., Hoet P.H. Co-cultures of multiple cell types mimic pulmonary cell communication in response to urban PM10. Eur. Respir. J. 2008, 32:1184-1194.
97. Klein S.G., Serchi T., Hoffmann L., Blömeke B., Gutleb A.C. An improved 3D tetraculture system mimicking the cellular organisation at the alveolar barrier to study the potential toxic effects of particles on the lung. Part. Fibre Toxicol. 2013, 10:31.
98. Huh D., Matthews B., Mammoto A., Montoya-Zavala M., Hsin H., Ingber D. Reconstituting organ-level lung functions on a chip. Science 2010, 328:1662-1668.
99. Huh D., Leslie D.C., Matthews B.D., Fraser J.P., Jurek S., Hamilton G.A., Thorneloe K.S., McAlexander M.A., Ingber D.E. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci. Transl. Med. 2012, 4. (159ra147).
100. WorldHealthOrganization Fact sheet N°104, Tuberculosis March 2014, (pp. http://www.who.int/mediacentre/factsheets/fs104/en/). W.H. Organization (Ed.).
101. Turkington C., Ashby B.L. The Encyclopedia of Infectious Diseases 2007, Facts on File, Incorporated. 3 ed.
102. McPhee S.J., Hammer G.D. Pathophysiology of Disease An Introduction to Clinical Medicine 2009, McGraw-Hill Medical. 6 ed.
103. Pommerville J.C. Alcamo's Fundamentals of Microbiology 2010, Jones & Bartlett Learning.
104. WorldHeathOrganization Fact sheet N°331, Pneumonia November 2013, pp http://www.who.int/mediacentre/factsheets/fs331/en/.
105. Ranganathan S.C., Sonnappa S. Pneumonia and other respiratory infections. Pediatr. Clin. N. Am. 2009, 56:135-156.
106. Nair G.B., Niederman M.S. Community-acquired pneumonia: an unfinished battle. Med. Clin. N. Am. 2011, 95:1143-1161.
107. Sharma S., Maycher B., Eschun G. Radiological imaging in pneumonia: recent innovations. Curr. Opin. Pulm. Med. 2007, 13:159-169.
108. Huang W., Yao Y., Long Q., Yang X., Sun W., Liu C., Jin X., Li Y., Chu X., Chen B., Ma Y. Immunization against multidrug-resistant Acinetobacter baumannii effectively protects mice in both pneumonia and sepsis models. PLoS ONE 2014, 9:e100727.
109. Eddy O.L. Community acquired pneumonia: from common pathogens to emerging resistance. Emerg. Med. Pract. 2005, 7:24.
110. Harris M., Clark J., Coote N., Fletcher P., Harnden A., McKean M., Thomson A. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011, 66. (ii1eii23).
111. Murphy T.F., Brauer A.L., Eschberger K., Lobbins P., Grove L., Cai X., Sethi S. Pseudomonas aeruginosain chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008, 177:853-860.
112. Papi A., Bellettato C.M., Braccioni F., Romagnoli M., Casolari P., Caramori G., Fabbri L.M., Johnston S.L. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006, 173:1114-1121.
113. Sethi S., Sethi R., Eschberger K., Lobbins P., Cai X., Grant B.J.B., Murphy T.F. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007, 176:356-361.
114. Hozbor D.F., Huang W., Yao Y., Long Q., Yang X., Sun W., Liu C., Jin X., li Y., Chu X., Chen B., Ma Y. Immunization against multidrug-resistant Acinetobacter baumannii effectively protects mice in both pneumonia and sepsis models. PLoS ONE 2014, 9:e100727.
115. Vlahos R., Bozinovski S. Recent advances in pre-clinical mouse models of COPD. Clin. Sci. 2014, 126:253-265.
116. Kurata S., Osaki T., Yonezawa H., Arae K., Taguchi H., Kamiya S. Role IL-17A and IL-10 in the antigen induced inflammation model by Mycoplasma pneumoniae. BMC Microbiol. 2014, 14:156.
117. Spaulding A.R., Salgado-Pabon W., Merriman J.A., Stach C.S., Ji Y., Gillman A.N., Peterson M.L., Schlievert P.M. Vaccination against Staphylococcus aureus pneumonia. J. Infect. Dis. 2014, 209:1955-1962.
118. Fliegauf M., Sonnen A.F., Kremer B., Henneke P. Mucociliary clearance defects in a murine in vitro model of pneumococcal airway infection. PLoS ONE 2013, 8:19.
119. Krunkosky T.M., Jordan J.L., Chambers E., Krause D.C. Mycoplasma pneumoniae host-pathogen studies in an air-liquid culture of differentiated human airway epithelial cells. Microb. Pathog. 2007, 42:98-103.
120. Adamson J., Haswell L.E., Phillips G., Gaça M.D. In Vitro Models of Chronic Obstructive Pulmonary Disease (COPD) 2011.
121. Retamales I., Elliott W.M., Meshi B., Coxson H.O., Pare P.D., Sciurba F.C., Rogers R.M., Hayashi S., Hogg J.C. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am. J. Respir. Crit. Care Med. 2001, 164:469-473.
122. Cosio M.G., Majo J. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest 2002, 121:160S-165S.
123. Hogg JC C.F., Utokaparch S., Woods R., Elliot M., Buzatu L., Cherniack R., Rogers R.M., Sciurba F.C., Coxson H.O., Paré P.D. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004, 350:2645-2653.
124. Huang S., Wiszniewski L., Derouette J.-P., Constant S. In vitro organ culture models of asthma. Drug Discov. Today 2009, 6:137-144.
125. Rosen S.H., Castleman B., Liebow A.A. Pulmonary alveolar proteinosis. N. Engl. J. Med. 1958, 258:1123-1142.
126. Frazier A.A., Franks T.J., Cooke E.O., Mohammed T.L., Pugatch R.D., Galvin J.R. From the archives of the AFIP: pulmonary alveolar proteinosis. Radiographics 2008, 28:883-899.
127. Xu Z., Jing J., Wang H., Xu F., Wang J. Pulmonary alveolar proteinosis in China: a systematic review of 241 cases. Respirology 2009, 14:761-766.
128. Mehrian P., Homayounfar N., Karimi M.A., Jafarzadeh H. Features of idiopathic pulmonary alveolar proteinosis in high resolution computed tomography. Pol. J. Radiol. 2014, 79:65-69.
129. Souza C.A., Marchiori E., Goncalves L.P., Meirelles G.S., Zanetti G., Escuissato D.L., Capobianco J., Souza A.S. Comparative study of clinical, pathological and HRCT findings of primary alveolar proteinosis and silicoproteinosis. Eur. J. Radiol. 2012, 81:371-378.
130. Menard K.J. Whole lung lavage in the treatment of pulmonary alveolar proteinosis. J. PeriAnesthesia Nurs. 2005, 20:114-126.
131. Ceruti M., Rodi G., Stella G.M., Adami A., Bolongaro A., Baritussio A., Pozzi E., Luisetti M. Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report. Orphanet J. Rare Dis. 2007, 2:14.
132. Shah P.L., Hansell D., Lawson P.R., Reid K.B., Morgan C. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax 2000, 55:67-77.
133. Stanley E., Lieschke G.J., Grail D., Metcalf D., Hodgson G., Gall J.A., Maher D.W., Cebon J., Sinickas V., Dunn A.R. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:5592-5596.
134. Shibasaki M., Hashimoto K., Okamoto M., Hayashi Y., Imaizumi K., Hashimoto N., Ozaki N., Yokoi T., Takagi K., Hasegawa Y., Shimokata K., Kawabe T. Up-regulation of surfactant protein production in a mouse model of secondary pulmonary alveolar proteinosis. Am. J. Respir. Cell Mol. Biol. 2009, 40:536-542.
135. Wu X., Li S., Wang X., Song Y., Chen Z., Jiang J., Bai C. Therapeutic role of terbutaline in a rat whole-lung lavage model. Exp. Lung Res. 2011, 37:542-548.
136. Lachmann N., Happle C., Ackermann M., Luttge D., Wetzke M., Merkert S., Hetzel M., Kensah G., Jara-Avaca M., Mucci A., Skuljec J., Dittrich A.M., Pfaff N., Brennig S., Schambach A., Steinemann D., Gohring G., Cantz T., Martin U., Schwerk N., Hansen G., Moritz T. Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. 2014, 189:167-182.
137. Bueno J. Antitubercular in vitro drug discovery: tools for begin the search. Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance, InTech 2012, P.-J. Cardona (Ed.).
138. Vaddady P.K., Lee R.E., Meibohm B. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. Futur. Med. Chem. 2010, 2:1355-1369.
139. Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nat. Rev. Immunol. 2012, 12:352-366.
140. Kapoor N., Pawar S., Sirakova T.D., Deb C., Warren W.L., Kolattukudy P.E. Human granuloma in vitro model, for TB dormancy and resuscitation. PLoS ONE 2013, 8:7.
141. Parasa V.R., Rahman M.J., Ngyuen Hoang A.T., Svensson M., Brighenti S., Lerm M. Modeling Mycobacterium tuberculosis early granuloma formation in experimental human lung tissue. Dis. Model. Mech. 2014, 7:281-288.
142. Fenaroli F., Westmoreland D., Benjaminsen J., Kolstad T., Skjeldal F.M., Meijer A.H., van der Vaart M., Ulanova L., Roos N., Nystrom B., Hildahl J., Griffiths G. Nanoparticles as drug delivery system against tuberculosis in zebrafish embryos: direct visualization and treatment. ACS Nano 2014, 8:7014-7026.
143. McShane H., Williams A. A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberc. 2014, 94:105-110. (Edinburgh, Scotland).
144. Dannenberg A.M. Perspectives on clinical and preclinical testing of new tuberculosis vaccines. Clin. Microbiol. Rev. 2010, 23:781-794.
145. Gupta U.D., Katoch V.M. Animal models of tuberculosis. Tuberculosis 2005, 85:277-293.
146. Padilla-Carlin D.J., McMurray D.N., Hickey A.J. The guinea pig as a model of infectious diseases. Comp. Med. 2008, 58:324-340.
147. Muttil P., Wang C., Hickey A.J. Inhaled drug delivery for tuberculosis therapy. Pharm. Res. 2009, 26:2401-2416.
148. Calderon V.E., Valbuena G., Goez Y., Judy B.M., Huante M.B., Sutjita P., Johnston R.K., Estes D.M., Hunter R.L., Actor J.K., Cirillo J.D., Endsley J.J. A humanized mouse model of tuberculosis. PLoS ONE 2013, 8.
149. Heuts F., Gavier-Widen D., Carow B., Juarez J., Wigzell H., Rottenberg M.E. CD4+ cell-dependent granuloma formation in humanized mice infected with mycobacteria. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:6482-6487.
150. Moreau-Marquis S., Stanton B.A., O'Toole G.A. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm. Pharmacol. Ther. 2008, 21:595-599.
151. Lyczak J.B., Cannon C.L., Pier G.B. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 2002, 15:194-222.
152. Saiman L., Siegel J.D., LiPuma J.J., Brown R.F., Bryson E.A., Chambers M.J., Downer V.S., Fliege J., Hazle L.A., Jain M., Marshall B.C., O'Malley C., Pattee S.R., Potter-Bynoe G., Reid S., Robinson K.A., Sabadosa K.A., Schmidt H.J., Tullis E., Webber J., Weber D.J. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect. Control Hosp. Epidemiol. 2014, 35:1-67.
153. Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2011, 9:32.
154. Döring G., Flume P., Heijerman H., Elborn J.S. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 2012, 11:461-479.
155. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel P.J., Willey-Courand D.B., Bujan J., Finder J., Lester M., Quittell L., Rosenblatt R., Vender R.L., Hazle L., Sabadosa K., Marshall B. Cystic fibrosis pulmonary guidelines. Am. J. Respir. Crit. Care Med. 2007, 176:957-969.
156. Flume P.A., Mogayzel P.J., Robinson K.A., Goss C.H., Rosenblatt R.L., Kuhn R.J., Marshall B.C. Cystic fibrosis pulmonary guidelines. Am. J. Respir. Crit. Care Med. 2009, 180:802-808.
157. Cassidy C., Tunney M., Magee N., Elborn J., Bell S., Singh T., Donnelly R. Drug and light delivery strategies for photodynamic antimicrobial chemotherapy (PACT) of pulmonary pathogens: a pilot study. Photodiagn. Photodyn. Ther. 2011, 8:1-6.
158. CysticFibrosisFoundation 2014.
159. Wine J.J. The development of lung disease in cystic fibrosis pigs. Sci. Transl. Med. 2010, 2:3001130.
160. Stoltz D.A., Meyerholz D.K., Pezzulo A.A., Ramachandran S., Rogan M.P., Davis G.J., Hanfland R.A., Wohlford-Lenane C., Dohrn C.L., Bartlett J.A., Nelson G.A.t., Chang E.H., Taft P.J., Ludwig P.S., Estin M., Hornick E.E., Launspach J.L., Samuel M., Rokhlina T., Karp P.H., Ostedgaard L.S., Uc A., Starner T.D., Horswill A.R., Brogden K.A., Prather R.S., Richter S.S., Shilyansky J., McCray P.B., Zabner J., Welsh M.J. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci. Transl. Med. 2010, 2:3000928.
161. Ehrhardt C., Collnot E.-M., Baldes C., Becker U., Laue M., Kim K.-J., Lehr C.-M. Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o. Cell Tissue Res. 2005, 323:405-415.
162. Gruenert D.C., Willems M., Cassiman J.J., Frizzell R.A. Established cell lines used in cystic fibrosis research. J. Cyst. Fibros. 2004, 3:191-196.
163. Sriramulu D.D., Lunsdorf H., Lam J.S., Romling U. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J. Med. Microbiol. 2005, 54:667-676.
164. Rubin B.K. Mucus structure and properties in cystic fibrosis. Paediatr. Respir. Rev. 2007, 8:4-7.
165. Haley C.L., Colmer-Hamood J.A., Hamood A.N. Characterization of biofilm-like structures formed by Pseudomonas aeruginosa in a synthetic mucus medium. BMC Microbiol. 2012, 12:1471-2180.
166. Kirchner S., Fothergill J.L., Wright E.A., James C.E., Mowat E., Winstanley C. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung. J. Visualized Exp. 2012, 5.
167. Macia M.D., Rojo-Molinero E., Oliver A. Antimicrobial susceptibility testing in biofilm-growing bacteria. Clin. Microbiol. Infect. 2014, 26:691-1469.
168. Swift S., Downie J.A., Whitehead N.A., Barnard A.M., Salmond G.P., Williams P. Quorum sensing as a population-density-dependent determinant of bacterial physiology. Adv. Microb. Physiol. 2001, 45:199-270.
169. Klein T., Henn C., de Jong J.C., Zimmer C., Kirsch B., Maurer C.K., Pistorius D., Muller R., Steinbach A., Hartmann R.W. Identification of small-molecule antagonists of the Pseudomonas aeruginosa transcriptional regulator PqsR: biophysically guided hit discovery and optimization. ACS Chem. Biol. 2012, 7:1496-1501.
170. Hunter R.C., Klepac-Ceraj V., Lorenzi M.M., Grotzinger H., Martin T.R., Newman D.K. Phenazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity. Am. J. Respir. Cell Mol. Biol. 2012, 47:738-745.
171. Nafee N., Husari A., Maurer C.K., Lu C., de Rossi C., Steinbach A., Hartmann R.W., Lehr C.M., Schneider M. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. J. Control. Release 2014, 3:464-467.
172. Anderson G.G., Moreau-Marquis S., Stanton B.A., O'Toole G.A. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect. Immun. 2008, 76:1423-1433.
173. Yu Q., Griffin E.F., Moreau-Marquis S., Schwartzman J.D., Stanton B.A., O'Toole G.A. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. J. Antimicrob. Chemother. 2012, 67:2673-2681.
174. Moreau-Marquis S., Redelman C.V., Stanton B.A., Anderson G.G. Co-culture models of Pseudomonas aeruginosa biofilms grown on live human airway cells. J. Visualized Exp. 2010, 1-4.
175. Bragonzi A., Farulla I., Paroni M., Twomey K.B., Pirone L., Lore N.I., Bianconi I., Dalmastri C., Ryan R.P., Bevivino A. Modelling co-infection of the cystic fibrosis lung by Pseudomonas aeruginosa and Burkholderia cenocepacia reveals influences on biofilm formation and host response. PLoS ONE 2012, 7:21.
176. Baldan R., Cigana C., Testa F., Bianconi I., De Simone M., Pellin D., Di Serio C., Bragonzi A., Cirillo D.M. Adaptation of Pseudomonas aeruginosa in cystic fibrosis airways influences virulence of staphylococcus aureus in vitro and murine models of co-infection. PLoS ONE 2014, 9:e89614.
177. Hoffmann N., Rasmussen T.B., Jensen P.O., Stub C., Hentzer M., Molin S., Ciofu O., Givskov M., Johansen H.K., Hoiby N. Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect. Immun. 2005, 73:2504-2514.
178. Puchelle E., Bajolet O., Abely M. Airway mucus in cystic fibrosis. Paediatr. Respir. Rev. 2002, 3:115-119.
179. OECD Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment No. 34 2005.
180. Hartung T., Bremer S., Casati S., Coecke S., Corvi R., Fortaner S., Gribaldo L., Halder M., Hoffmann S., Roi A.J., Prieto P., Sabbioni E., Scott L., Worth A., Zuang V. A modular approach to the ECVAM principles on test validity. Altern. Lab. Anim. 2004, 32:467-472.